| Welcome to the Proximagen Newsroom. In this section you will find information not only about Proximagen, but about the latest in neurodegenerative research. Check back often for updates.
Publication: Financial Times
Date: 15 March 2005
Words: 93
Proximagen to list on Aim
Proximagen Neuroscience, the drug development company focused on neurodegenerative diseases, plans to join Aim at the end of this month.
The company was founded in November 2003 by Professor Peter Jenner and King's College, London. IP2IPO, the intellectual property company that commercialises university technology, has a 46.1 per cent stake.
Proximagen aims to raise up to £12m in a placing of shares to institutions to finance drug development programmes for Parkinson’s and Alzheimer’s diseases. The market capitalisation is expected to be about £30m. KBC Peel Hunt is adviser and broker.
| 
